{"id":"iloprost-5-g","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Headache"},{"rate":"20-30%","effect":"Dizziness"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Flushing"},{"rate":"5-10%","effect":"Palpitations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Iloprost works by binding to and activating the prostacyclin receptor, leading to relaxation of vascular smooth muscle and inhibition of platelet aggregation. This results in vasodilation and improved blood flow, which can be beneficial in treating conditions such as pulmonary arterial hypertension.","oneSentence":"Iloprost is a prostacyclin analogue that acts as a vasodilator and inhibits platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:17.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"}]},"trialDetails":[{"nctId":"NCT00709956","phase":"PHASE3","title":"Iloprost Power 15 in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2008-07","conditions":"Pulmonary Arterial Hypertension","enrollment":64},{"nctId":"NCT03044314","phase":"PHASE4","title":"Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension","status":"TERMINATED","sponsor":"Duke University","startDate":"2017-07-21","conditions":"Pulmonary Hypertension","enrollment":27},{"nctId":"NCT02482402","phase":"PHASE2","title":"Iloprost for Bridging to Heart Transplantation in PH","status":"WITHDRAWN","sponsor":"Heidelberg University","startDate":"2015-02","conditions":"Chronic Left Ventricular Failure, Pulmonary Hypertension","enrollment":""},{"nctId":"NCT02032836","phase":"PHASE1, PHASE2","title":"Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-10","conditions":"Pulmonary Arterial Hypertension","enrollment":27},{"nctId":"NCT00467896","phase":"PHASE2","title":"The \"Power 15 Study\": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting","status":"TERMINATED","sponsor":"Actelion","startDate":"2006-09","conditions":"Pulmonary Hypertension","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ventavis(R)"],"phase":"phase_3","status":"active","brandName":"iloprost (5 µg)","genericName":"iloprost (5 µg)","companyName":"Actelion","companyId":"actelion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iloprost is a prostacyclin analogue that acts as a vasodilator and inhibits platelet aggregation. Used for Pulmonary arterial hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}